Galectin Therapeutics
GALT
94 hedge funds and large institutions have $13M invested in Galectin Therapeutics in 2024 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 35 increasing their positions, 12 reducing their positions, and 6 closing their positions.
250% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 6
192% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 12
19% more funds holding
Funds holding: 79 → 94 (+15)
0.55% more ownership
Funds ownership: 15.65% → 16.2% (+0.55%)
23% less call options, than puts
Call options by funds: $5.86M | Put options by funds: $7.59M
52% less capital invested
Capital invested by funds: $26.8M → $13M (-$13.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RGF
Retirement Guys Formula
Maumee,
Ohio
|
+$219K |
| 2 |
LPL Financial
San Diego,
California
|
+$137K |
| 3 |
BlackRock
New York
|
+$107K |
| 4 |
Morgan Stanley
New York
|
+$105K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$89.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$836K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$171K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$144K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$81K |
| 5 |
Squarepoint
New York
|
-$75.4K |
GALT Hedge Fund Activity: Q4 2024 in Review
94 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2024, worth a combined $13M — down 52% from $26.8M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new GALT positions and 6 closed out — a net gain of 15 holders — while 35 added to existing stakes and 12 trimmed.
The largest buyer was Retirement Guys Formula, adding an estimated $219K. The largest seller was Commonwealth Equity Services, cutting an estimated $836K.
- 94 institutional investors held Galectin Therapeutics (GALT) as of Q4 2024, up from 79 in Q3 2024.
- Funds reported $13M of Galectin Therapeutics stock for Q4 2024, down 52% quarter-over-quarter.
- 21 funds opened new Galectin Therapeutics positions in Q4 2024 and 6 closed out, a net change of +15 holders.
- The largest Galectin Therapeutics buyer in Q4 2024 was Retirement Guys Formula, an estimated $219K added.
- The largest Galectin Therapeutics seller in Q4 2024 was Commonwealth Equity Services, an estimated $836K sold.
Based on aggregated 13F filings for Q4 2024.